GB1403900A - Pharmaceutical composition - Google Patents

Pharmaceutical composition

Info

Publication number
GB1403900A
GB1403900A GB5049572A GB5049572A GB1403900A GB 1403900 A GB1403900 A GB 1403900A GB 5049572 A GB5049572 A GB 5049572A GB 5049572 A GB5049572 A GB 5049572A GB 1403900 A GB1403900 A GB 1403900A
Authority
GB
United Kingdom
Prior art keywords
ion source
pharmaceutical composition
nov
active ingredients
magnesium ion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB5049572A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chinoin Private Co Ltd
Original Assignee
Chinoin Gyogyszer es Vegyeszeti Termekek Gyara Zrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chinoin Gyogyszer es Vegyeszeti Termekek Gyara Zrt filed Critical Chinoin Gyogyszer es Vegyeszeti Termekek Gyara Zrt
Publication of GB1403900A publication Critical patent/GB1403900A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

1403900 Oral compositions CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT 2 Nov 1972 [8 Nov 1971] 50495/72 Heading A5B An oral pharmaceutical composition for the prevention or relief of renal calculi comprises as active ingredients at least one magnesium ion source, at least one citrate ion source and vitamin B 6 , the magnesium ion source and the citrate ion source being in the proportions of 2-20% and 66-98.5% respectively based on the weight of active ingredients, and optionally solid or liquid pharmaceutical carriers or diluents.
GB5049572A 1971-11-08 1972-11-02 Pharmaceutical composition Expired GB1403900A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HUCI1185A HU165181B (en) 1971-11-08 1971-11-08

Publications (1)

Publication Number Publication Date
GB1403900A true GB1403900A (en) 1975-08-28

Family

ID=10994422

Family Applications (1)

Application Number Title Priority Date Filing Date
GB5049572A Expired GB1403900A (en) 1971-11-08 1972-11-02 Pharmaceutical composition

Country Status (9)

Country Link
AT (1) AT332531B (en)
CA (1) CA978479A (en)
CS (1) CS217603B1 (en)
DD (1) DD100631A1 (en)
DE (1) DE2252665A1 (en)
GB (1) GB1403900A (en)
HU (1) HU165181B (en)
IL (1) IL40685A (en)
SU (1) SU1009467A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960108A (en) * 1987-08-28 1990-10-02 Leopold & Co. Chem. Pharm. Fabrik Gesellschaft M.B.H. Laser-induced shockwave lithotripsy
JPH03223228A (en) * 1989-02-07 1991-10-02 Misson Pharmacal Co Inc Preparation of composition of potassium magnesium citrate
WO2009143021A1 (en) * 2008-05-22 2009-11-26 Bristol-Myers Squibb Company Method for treating and preventing kidney stones employing an sglt2 inhibitor and composition containing same
JP2016513474A (en) * 2013-03-15 2016-05-16 ニューヨーク ユニバーシティ Beverages containing citrate
US9636304B2 (en) 2010-11-18 2017-05-02 Advicenne Pharmaceutical composition comprising citrate and bicarbonate salts, and use thereof for treating cystinuria
US9782352B2 (en) 2010-11-18 2017-10-10 Advicenne Pharmaceutical composition comprising Krebs cycle precursor salt, in particular citrate salt, and use thereof as a medicament

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2826642C2 (en) 1978-06-19 1987-04-23 Dr. Madaus & Co, 5000 Köln Oral urolithiasis agent
DE3046580A1 (en) * 1980-12-11 1982-07-01 Leskovar, Peter, Dr.-Ing., 8000 München Prophylactic and curative treatment of urinary calculi - by admin. of organic acid, dye, metal oxide, etc.
CA1326040C (en) * 1989-11-16 1994-01-11 Neill B. Walsdorf Magnesium-potassium citrate
DE4409949C2 (en) * 1994-03-23 1996-11-21 Madaus Ag Use of calcium alkali citrates for the prophylaxis and treatment of degenerative diseases of the bone structure
DE10028167B4 (en) * 2000-06-09 2004-02-19 Storch, Rüdiger, Dr. Use of calcium salts to counteract the formation of oxalate stones

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3328304A (en) * 1964-07-31 1967-06-27 Guardian Chemical Corp Chelating agents and methods for their manufacture
FR2019261A1 (en) * 1969-03-19 1970-07-03 Melon Jean Marie Treatment of oxalic lithiase with succinic - acid and its derivs

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960108A (en) * 1987-08-28 1990-10-02 Leopold & Co. Chem. Pharm. Fabrik Gesellschaft M.B.H. Laser-induced shockwave lithotripsy
JPH03223228A (en) * 1989-02-07 1991-10-02 Misson Pharmacal Co Inc Preparation of composition of potassium magnesium citrate
JP2545479B2 (en) 1989-02-07 1996-10-16 ミッション ファーマカル カンパニー，インコーポレーテッド Pharmaceutical composition
WO2009143021A1 (en) * 2008-05-22 2009-11-26 Bristol-Myers Squibb Company Method for treating and preventing kidney stones employing an sglt2 inhibitor and composition containing same
US8603989B2 (en) 2008-05-22 2013-12-10 Bristol-Myers Squibb Company Method for treating and preventing kidney stones employing an SGLT2 inhibitor and composition containing same
US9636304B2 (en) 2010-11-18 2017-05-02 Advicenne Pharmaceutical composition comprising citrate and bicarbonate salts, and use thereof for treating cystinuria
US9782352B2 (en) 2010-11-18 2017-10-10 Advicenne Pharmaceutical composition comprising Krebs cycle precursor salt, in particular citrate salt, and use thereof as a medicament
JP2016513474A (en) * 2013-03-15 2016-05-16 ニューヨーク ユニバーシティ Beverages containing citrate
US10258645B2 (en) 2013-03-15 2019-04-16 New York University Citrate containing beverage

Also Published As

Publication number Publication date
IL40685A (en) 1976-08-31
SU1009467A1 (en) 1983-04-07
DE2252665C2 (en) 1987-09-10
CA978479A (en) 1975-11-25
AT332531B (en) 1976-10-11
DE2252665A1 (en) 1973-05-10
HU165181B (en) 1974-07-27
CS217603B1 (en) 1983-01-28
ATA925372A (en) 1976-01-15
IL40685A0 (en) 1972-12-29
DD100631A1 (en) 1973-10-05

Similar Documents

Publication Publication Date Title
GB1325688A (en) Self propelled harvesting machine
GB1403900A (en) Pharmaceutical composition
SE8901041D0 (en) ANTITROMOBOTIC PHARMACEUTICAL PREPARATIONS AND PROCEDURES FOR THEIR PREPARATION
GB1270781A (en) Tableting medium
GB1464200A (en) Pharmaceutical composition
GB1341794A (en) Medicament for the treatment of hepatic disorders
CA936533A (en) 5-aryl-2,3-dihydro-2,2(or 3,3) dimethyl-5h-imidazo(2,1-a) isoindol-5-ols and 2(4,4(5,5) dimethyl-2-imidazolin-2-yl) bensophenone acid addition salts and processes for their preparation
GB1250725A (en)
GB1318169A (en) Moulded pharmaceutical compositions
GB1270049A (en) New pharmaceutical product
ES421299A1 (en) Medicament preparations
IE34609B1 (en) Antineoplastic therapeutic compositions
CA1008461A (en) 3,4-dihydroxyphenyl-alamines as active ingredients of antioxidant compositions
GB1180574A (en) Improvements in or relating to Injectable Thyroxine Preparations
GB1287433A (en) Pharmaceutical compositions
ES415670A1 (en) Dichlorobenzaldehyde-oxime-carbonates
GB1353834A (en) Benzenesulphonamides
GB1449043A (en) Treatment of asthma
CA953715A (en) N(6)-(2,5-dimethylbenzyl)-2-chloroadenosine derivatives, process for their preparation and pharmaceutical compositions containing the same
GB1449441A (en) Agnets for lowering the lipid level in plasma
GB1264695A (en)
GB1454872A (en) Anticonvulsant
CA945544A (en) 16-METHYLENE-9.beta., 10.alpha.-STEROID COMPOUNDS, PHARMACEUTICAL PREPARATIONS WHICH CONTAIN THE NOVEL COMPOUNDS AS ACTIVE INGREDIENTS, AND METHODS OF PRODUCING THE SAID COMPOUNDSAND PREPARATIONS
CA849567A (en) Alpha-(2-hydroxy-3,5,6-trichloro)-phenylglycol acid and biocidal compositions
GB1296625A (en)

Legal Events

Date Code Title Description
PS Patent sealed [section 19, patents act 1949]
435 Patent endorsed 'licences of right' on the date specified (sect. 35/1949)
PE20 Patent expired after termination of 20 years